Results 191 to 200 of about 93,014 (296)

Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases

The Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley   +1 more source

Words matter: reclassifying chronic pruritus of unknown origin as neuroimmune pruritus. [PDF]

JAAD Int
Verma H, Brownstone N.
europepmc   +1 more source

Remission of refractory lichen amyloidosis with baricitinib. [PDF]

An Bras Dermatol
da Silva TL, Duarte GV.
europepmc   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source

Study of Clinico-demography and Impact on Quality of Life of Patients with Scalp Pruritus. [PDF]

Indian Dermatol Online J
Varshney A, Dsouza P, Rastogi P, Arora J.   +3 more
europepmc   +1 more source

Minimal Clinically Important Difference in Chronic Pruritus Appears to be Dependent on Baseline Itch Severity

Acta Dermato-Venereologica, 2019
Claudia Riepe, Nani Osada, Adam Reich, Matthias Augustin, Claudia Zeidler, Sonja Ständer   +5 more
doaj   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source

Case Report: Successful treatment of dystrophic epidermolysis bullosa pruriginosa with upadacitinib in a patient with <i>COL7A1</i>, <i>CARD14</i>, and <i>G6PD</i> gene mutations. [PDF]

Front Med (Lausanne)
Li H, Zhang Y, Lin X, Yan T, Wu X, Zhang Z.   +5 more
europepmc   +1 more source

Pruritus in Melancholia [PDF]

BMJ, 1954
openaire   +2 more sources

Culturally Safe and Decentralised Care: Patient Experiences of a Dermatology Clinic Embedded in an Aboriginal and Torres Strait Islander Primary Health Care Service

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background Skin disease is a major cause of morbidity in Australia and a leading reason for primary care visits. Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of skin conditions but face barriers to accessing culturally safe specialist services.
Nikhil Dwivedi, Nicholas Van Rooij, Geoffrey Spurling, Claudette (Sissy) Tyson, Sonya Egert, Erin McMeniman, Noel Hayman   +6 more
wiley   +1 more source